Showing results (181-190 of 215) with videos related to
Sort By:
Pageof 22
Inflammatory Bowel Diseases|September 9, 2016
Preoperative Anti-tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After Ileal Pouch-anal AnastomosisEran Zittan, Raquel Milgrom, Grace W Ma, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 19, 2018
Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort StudyLaura E Targownik, Eric I Benchimol, Charles N Bernstein, et al.Gastroenterology|January 28, 2014
Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of GastroenterologyGeoffrey C Nguyen, Charles N Bernstein, Alain Bitton, et al.Journal of Crohn'S & Colitis|July 11, 2020
Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related ComplicationsLaura E Targownik, Eric I Benchimol, Charles N Bernstein, et al.Journal of the Canadian Association of Gastroenterology|July 12, 2019
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBDMatthew W Carroll, M Ellen Kuenzig, David R Mack, et al.Neurogastroenterology and Motility|November 15, 2022
Impact of antegrade enema initiation on healthcare utilization in pediatric patients: A population-based cohort studyMichelle J Gould, Margaret A Marcon, Geoffrey C Nguyen, et al.Inflammatory Bowel Diseases|June 19, 2019
The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel DiseaseLaura E Targownik, Eric I Benchimol, Julia Witt, et al.The American Journal of Gastroenterology|January 3, 2020
Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based AnalysisLaura E Targownik, Gilaad G Kaplan, Julia Witt, et al.Inflammatory Bowel Diseases|October 23, 2018
Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness MethodologyAdam V Weizman, Geoffrey C Nguyen, Cynthia H Seow, et al.Journal of the Canadian Association of Gastroenterology|November 10, 2021
Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBDCharles N Bernstein, Harminder Singh, Sanjay K Murthy, et al.Pageof 22